Focused on Corneal Therapeutics

Breaking News  

February 10, 2020
Trefoil Therapeutics Appoints Thomas M. Tremblay, RN BSN, Vice President, Clinical Development
Experienced executive to lead corneal disease clinical program for TTHX1114 

Trefoil Therapeutics today announced the appointment of Thomas M. Tremblay, RN, BSN to the newly created position of Vice President, Clinical Development. He brings to Trefoil more than 25 years of experience in pharmaceutical development across a variety of therapeutic areas.


Recruiting for a Senior Scientist.  Details HERE

Trefoil is a biotechnology company focused on leveraging its engineered fibroblast growth factor-1 protein (eFGF-1) technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which are debilitating and cause a significant amount of preventable blindness throughout the world.

Lead candidate TTHX1114 is an engineered form of FGF-1 designed to stimulate proliferation and migration of corneal endothelial cells. It is initially being developed as an intracameral injection as the first pharmacologic treatment for back of the cornea surface disease (endothelial dystrophy), the leading cause of cornea transplantation surgeries.

Trefoil's second development program focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision.

© 2018 by Trefoil Therapeutics, Inc.